Search research articles
Contact Us
Filters
Showing results (31-40 of 82) with videos related to
Page
of 9
Sort By:
BMJ (Clinical Research Ed.)
|
June 25, 2020
Reconsidering the scope of US state laws allowing pharmacist substitution of generic drugs
Jonathan J Darrow, Jessica E Chong, Aaron S Kesselheim
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics
|
April 18, 2019
Approximating Future Generic Entry for New Drugs
Reed F Beall, Jonathan J Darrow, Aaron S Kesselheim
Applied Health Economics and Health Policy
|
August 25, 2018
The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents
Jonathan J Darrow, Reed F Beall, Aaron S Kesselheim
Drug Discovery Today
|
July 29, 2018
Patent term restoration for top-selling drugs in the United States
Reed F Beall, Jonathan J Darrow, Aaron S Kesselheim
Nature Biotechnology
|
December 9, 2017
Will inter partes review speed US generic drug entry?
Jonathan J Darrow, Reed F Beall, Aaron S Kesselheim
JAMA
|
December 7, 2017
The FDA's Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016
Thomas J Hwang, Jonathan J Darrow, Aaron S Kesselheim
American Journal of Public Health
|
June 16, 2022
Government Patent Use to Promote Public Health in the United States: Overcoming Nonpatent Exclusivities
Rebecca E Wolitz, Aaron S Kesselheim, Jonathan J Darrow
Chest
|
January 9, 2018
Pharmaceutical Advertising in Medical Journals: Revisiting a Long-Standing Relationship
Michael S Sinha, Aaron S Kesselheim, Jonathan J Darrow
Nature Biotechnology
|
February 16, 2022
Recent Orange and Purple Book legislation suggests a need to bridge drug and biologic patent regimes
Bryan S Walsh, Jonathan J Darrow, Aaron S Kesselheim
Journal of General Internal Medicine
|
April 9, 2021
Changing FDA Approval Standards: Ethical Implications for Patient Consent
Jonathan J Darrow, Sanket S Dhruva, Rita F Redberg
Page
of 9
Search research articles
Search
Showing results (31-40 of 82) with videos related to
Sort By:
Page
of 9
BMJ (Clinical Research Ed.)
|
June 25, 2020
Reconsidering the scope of US state laws allowing pharmacist substitution of generic drugs
Jonathan J Darrow, Jessica E Chong, Aaron S Kesselheim
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics
|
April 18, 2019
Approximating Future Generic Entry for New Drugs
Reed F Beall, Jonathan J Darrow, Aaron S Kesselheim
Applied Health Economics and Health Policy
|
August 25, 2018
The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents
Jonathan J Darrow, Reed F Beall, Aaron S Kesselheim
Drug Discovery Today
|
July 29, 2018
Patent term restoration for top-selling drugs in the United States
Reed F Beall, Jonathan J Darrow, Aaron S Kesselheim
Nature Biotechnology
|
December 9, 2017
Will inter partes review speed US generic drug entry?
Jonathan J Darrow, Reed F Beall, Aaron S Kesselheim
JAMA
|
December 7, 2017
The FDA's Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016
Thomas J Hwang, Jonathan J Darrow, Aaron S Kesselheim
American Journal of Public Health
|
June 16, 2022
Government Patent Use to Promote Public Health in the United States: Overcoming Nonpatent Exclusivities
Rebecca E Wolitz, Aaron S Kesselheim, Jonathan J Darrow
Chest
|
January 9, 2018
Pharmaceutical Advertising in Medical Journals: Revisiting a Long-Standing Relationship
Michael S Sinha, Aaron S Kesselheim, Jonathan J Darrow
Nature Biotechnology
|
February 16, 2022
Recent Orange and Purple Book legislation suggests a need to bridge drug and biologic patent regimes
Bryan S Walsh, Jonathan J Darrow, Aaron S Kesselheim
Journal of General Internal Medicine
|
April 9, 2021
Changing FDA Approval Standards: Ethical Implications for Patient Consent
Jonathan J Darrow, Sanket S Dhruva, Rita F Redberg
Page
of 9